First Study Shows CB1 Receptor Modulator Org27569 Reduces Baseline Signaling Through a Specific Pathway
The CB1 receptor allosteric modulator Org27569 was shown to act as an inverse agonist of ERK signaling, reducing baseline activity and blocking CB1 receptor internalization triggered by synthetic cannabinoids.
Quick Facts
What This Study Found
Allosteric modulators bind to a different site on a receptor than the primary binding site, offering a way to fine-tune receptor activity rather than simply turning it on or off. Org27569 is the most-studied allosteric modulator of the CB1 cannabinoid receptor.
This study resolved conflicting reports about how Org27569 affects ERK signaling, a key pathway through which cannabinoid receptors influence cell behavior. The researchers found that Org27569 fully blocked ERK activation triggered by the synthetic cannabinoid CP55,940 but could not completely block ERK activation by THC or 2-AG (the body's own cannabinoid).
Org27569 also reduced baseline ERK activity below normal levels, an effect mediated specifically through CB1 receptors and their associated G-proteins. This is the first demonstration of ERK inverse agonism by Org27569.
Key Numbers
CP55,940 (1 uM) produced significant receptor internalization at 20, 40, 60, and 120 minutes. Org27569 (10 uM) fully prevented this internalization. Org27569 reduced basal ERK phosphorylation in CB1-expressing cells but not untransfected cells. Effects were observed in both nuclear and cytosolic cell fractions.
How They Did This
Cell-based experiments using HEK293 cells expressing human CB1 receptors. Researchers measured G-protein activation, ERK phosphorylation, receptor internalization via confocal imaging, and subcellular fractionation to determine where in the cell ERK changes occurred. Pertussis toxin was used to confirm the role of Gi/o proteins.
Why This Research Matters
Allosteric modulators represent a frontier in cannabinoid drug development because they could theoretically dial cannabinoid receptor activity up or down without the all-or-nothing effects of current drugs. Understanding exactly how Org27569 affects signaling pathways is essential for developing this approach into practical therapies.
The Bigger Picture
Most current cannabinoid drugs work by directly activating or blocking CB1 or CB2 receptors. Allosteric modulators represent a fundamentally different approach that could allow more nuanced control of the endocannabinoid system, potentially reducing side effects while preserving therapeutic benefits.
What This Study Doesn't Tell Us
All experiments were in cell cultures overexpressing CB1 receptors, which may not reflect receptor behavior in living brains. The concentrations used may not be achievable in vivo. The clinical relevance of ERK inverse agonism at CB1 receptors remains to be determined.
Questions This Raises
- ?Could allosteric modulators like Org27569 or its derivatives be developed into practical treatments?
- ?Why does Org27569 fully block CP55,940 but not THC-mediated ERK signaling?
Trust & Context
- Key Stat:
- First demonstration of ERK inverse agonism by a CB1 allosteric modulator
- Evidence Grade:
- Rigorous cell-based mechanistic study with multiple confirmatory approaches, but entirely in vitro with no clinical relevance established.
- Study Age:
- Published in 2016. Allosteric modulator research has continued to evolve since.
- Original Title:
- CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling.
- Published In:
- Cannabis and cannabinoid research, 1(1), 272-280 (2016)
- Authors:
- Gamage, Thomas F(5), Anderson, Johnathon C, Abood, Mary E(3)
- Database ID:
- RTHC-01159
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is an allosteric modulator?
It's a compound that binds to a different spot on a receptor than the main binding site, allowing it to adjust receptor activity more subtly than drugs that directly activate or block the receptor.
Why is this finding important for drug development?
Understanding exactly how allosteric modulators change cannabinoid receptor signaling is essential for designing drugs that could fine-tune the endocannabinoid system for therapeutic purposes with fewer side effects.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01159APA
Gamage, Thomas F; Anderson, Johnathon C; Abood, Mary E. (2016). CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling.. Cannabis and cannabinoid research, 1(1), 272-280. https://doi.org/10.1089/can.2016.0028
MLA
Gamage, Thomas F, et al. "CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling.." Cannabis and cannabinoid research, 2016. https://doi.org/10.1089/can.2016.0028
RethinkTHC
RethinkTHC Research Database. "CB1 allosteric modulator Org27569 is an antagonist/inverse a..." RTHC-01159. Retrieved from https://rethinkthc.com/research/gamage-2016-cb1-allosteric-modulator-org27569
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.